Tumori · 2020
Anlotinib in treatment of an elderly patient with recurrent advanced SCLC.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Ying, Jia Beili, Li Jing, Xu Xiaomei
Аннотация
INTRODUCTION: An elderly patient with advanced small cell lung cancer who had a history of smoking and who had previously had tuberculosis and chronic kidney disease relapsed after classical treatment with etoposide combined with carboplatin.
METHODS: The patient was given chemotherapy again, with albumin-bound paclitaxel, etoposide capsules, apatinib, and other treatment. The last medication was apatinib.
RESULTS: After treatment with anlotinib, the patient has survived for 15 months with good quality of life.
CONCLUSION: This is the first report on the precise efficacy of anlotinib in the treatment of advanced small cell lung cancer. Anlotinib is an important option for patients with small cell lung cancer.
METHODS: The patient was given chemotherapy again, with albumin-bound paclitaxel, etoposide capsules, apatinib, and other treatment. The last medication was apatinib.
RESULTS: After treatment with anlotinib, the patient has survived for 15 months with good quality of life.
CONCLUSION: This is the first report on the precise efficacy of anlotinib in the treatment of advanced small cell lung cancer. Anlotinib is an important option for patients with small cell lung cancer.